X Montalban

Summary

Publications

  1. ncbi request reprint Interferons and cognition
    X Montalban
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neurol Sci 245:137-40. 2006
  2. ncbi request reprint Primary progressive multiple sclerosis
    Xavier Montalban
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Curr Opin Neurol 18:261-6. 2005
  3. doi request reprint Early treatment: PreCISe-ly what the patient needs
    Xavier Montalban
    Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neurol Sci 287:S2-6. 2009
  4. pmc Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis
    Nicolas Fissolo
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroinflammation 9:139. 2012
  5. doi request reprint Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study
    X Montalban
    Unitat de Neuroimmunologia Clinica, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 17:1341-50. 2011
  6. doi request reprint Primary progressive multiple sclerosis diagnostic criteria: a reappraisal
    X Montalban
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Center of Catalonia CEMCat and Unitat de Ressonància Magnètica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 15:1459-65. 2009
  7. doi request reprint MRI criteria for MS in patients with clinically isolated syndromes
    X Montalban
    Unit of Clinical Neuroimmunology, EUI 2 P, Hospital Universitari Vall d Hebron, Paseig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 74:427-34. 2010
  8. doi request reprint A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
    X Montalban
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat, Barcelona, Spain
    Mult Scler 15:1195-205. 2009
  9. doi request reprint Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up
    Carmen Tur
    Multiple Sclerosis Centre of Catalonia, Autonomous University of Barcelona, Centre d Anàlisi i Recerca en Neuroimatge i Esclerosi Mùltiple Vall d Hebron University Hospital, Escola Universitària d Infermeria 2ª planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 68:1421-7. 2011
  10. ncbi request reprint MS treatment: postmarketing studies
    X Montalban
    EUI planta 2, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol Sci 259:42-5. 2007

Collaborators

Detail Information

Publications136 found, 100 shown here

  1. ncbi request reprint Interferons and cognition
    X Montalban
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neurol Sci 245:137-40. 2006
    ..The data that we have are not conclusive. This paper reviews the effect of IFNbeta on cognition in the different clinical forms of the disease and the future directions of clinical trials...
  2. ncbi request reprint Primary progressive multiple sclerosis
    Xavier Montalban
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Curr Opin Neurol 18:261-6. 2005
    ..The present article reviews the currently ongoing scientific debate on the specific characteristics of primary progressive multiple sclerosis...
  3. doi request reprint Early treatment: PreCISe-ly what the patient needs
    Xavier Montalban
    Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Neurol Sci 287:S2-6. 2009
    ..Considering these and previous results, this treatment should be regarded as an essential addition to the armamentarium of drugs available for the earliest treatment of this devastating disease...
  4. pmc Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis
    Nicolas Fissolo
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroinflammation 9:139. 2012
    ....
  5. doi request reprint Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study
    X Montalban
    Unitat de Neuroimmunologia Clinica, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 17:1341-50. 2011
    ..Health-related quality of life (HRQoL) worsens with multiple sclerosis (MS) relapses and disease progression. Common symptoms including depression and fatigue may contribute to poor HRQoL...
  6. doi request reprint Primary progressive multiple sclerosis diagnostic criteria: a reappraisal
    X Montalban
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Center of Catalonia CEMCat and Unitat de Ressonància Magnètica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 15:1459-65. 2009
    ..Unification of the DIS criteria for both RRMS and PPMS could be considered in further revisions of the MS diagnostic criteria...
  7. doi request reprint MRI criteria for MS in patients with clinically isolated syndromes
    X Montalban
    Unit of Clinical Neuroimmunology, EUI 2 P, Hospital Universitari Vall d Hebron, Paseig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 74:427-34. 2010
    ..New data that are now published were reviewed and discussed and together with a new proposal are integrated in this position paper...
  8. doi request reprint A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
    X Montalban
    Unitat de Neuroimmunologia Clinica, Multiple Sclerosis Centre of Catalonia CEM Cat, Barcelona, Spain
    Mult Scler 15:1195-205. 2009
    ..Positive effects of interferon beta on secondary clinical and magnetic resonance imaging outcomes were observed, but a beneficial effect on Expanded Disability Status Scale progression was not demonstrated...
  9. doi request reprint Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up
    Carmen Tur
    Multiple Sclerosis Centre of Catalonia, Autonomous University of Barcelona, Centre d Anàlisi i Recerca en Neuroimatge i Esclerosi Mùltiple Vall d Hebron University Hospital, Escola Universitària d Infermeria 2ª planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 68:1421-7. 2011
    ....
  10. ncbi request reprint MS treatment: postmarketing studies
    X Montalban
    EUI planta 2, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol Sci 259:42-5. 2007
    ..Despite the efficacy reported, a high proportion of patients will have a lack of response to treatment. Early identification of these patients is therefore essential in order to attempt other therapeutic approaches...
  11. ncbi request reprint Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
    M Tintore
    Unit of Clinical Neuroimmunology, Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Neurology 70:1079-83. 2008
    ..To evaluate whether oligoclonal bands (OB) add information to MRI in predicting both a second attack and development of disability in patients with clinically isolated syndromes (CIS)...
  12. doi request reprint Brainstem lesions in clinically isolated syndromes
    M Tintore
    Unitat de Neuroimmunologia Clinica UNIC, Edif Escola d Infermeria Planta 2, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neurology 75:1933-8. 2010
    ..Number of baseline lesions has been shown to predict future attacks and disability in clinically isolated syndromes (CIS)...
  13. doi request reprint Genetic association of CASP8 polymorphisms with primary progressive multiple sclerosis
    M Camina-Tato
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Departament de Medicina de la Universitat Autònoma de Barcelona, Barcelona, Spain
    J Neuroimmunol 222:70-5. 2010
    ..GG homozygosity for SNP rs2037815 in PPMS patients was associated with a trend towards faster disease progression. These findings point to a role of CASP8 polymorphisms in the MS genetic risk in PPMS patients...
  14. doi request reprint Do multimodal evoked potentials add information to MRI in clinically isolated syndromes?
    R Pelayo
    Multiple Sclerosis Center of Catalonia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mult Scler 16:55-61. 2010
    ..However, the utility of MMEPs is limited by the low percentage of CIS patients having the three abnormal at baseline...
  15. ncbi request reprint Baseline MRI predicts future attacks and disability in clinically isolated syndromes
    M Tintore
    Unit of Clinical Neuroimmunology Department of Neurology, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Spain
    Neurology 67:968-72. 2006
    ..To determine the relation between baseline MRI and both conversion to multiple sclerosis (MS) and development of disability in a cohort of patients with clinically isolated syndromes (CIS)...
  16. doi request reprint HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Departament de Medicina, Universitat Autonoma de Barcelona corrected Barcelona, Spain
    J Neuroimmunol 210:116-9. 2009
    ..These findings do not support a role of the HLA class I and class II genes as modifiers of the response to IFNbeta...
  17. doi request reprint Measures in the first year of therapy predict the response to interferon beta in MS
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 15:848-53. 2009
    ..Hence, the aim of this study was to investigate magnetic resonance imaging (MRI) and clinical predictors of response during the first 12 months of therapy...
  18. ncbi request reprint Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta?
    X Montalban
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    J Neurol 247:259-62. 2000
    ..In vitro stimulation of peripheral blood leukocytes with interferon-beta1b before the beginning of therapy shows that patients who develop fever generally have increased levels of interleukin-6...
  19. doi request reprint Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Edif EUI 2a planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 255:1136-41. 2008
    ....
  20. ncbi request reprint Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS
    M Tintore
    Unit of Clinical Neuroimmunology Department of Neurology, Vall d Hebron University Hospitals, Barcelona, Spain
    Mult Scler 7:359-63. 2001
    ..To evaluate and compare the capacity of oligoclonal bands (OB) and three sets of MR imaging criteria to predict the conversion of clinically isolated syndromes (CIS) to clinically definite multiple sclerosis (CDMS)...
  21. ncbi request reprint Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients
    C Lopez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Mult Scler 12:421-7. 2006
    ..These findings indicate immunomodulatory effects of pregnancy on the expression of chemokine receptors and cytokines, which may be related to changes in the clinical disease activity of T cell-mediated autoimmune diseases, such as MS...
  22. doi request reprint Very early scans for demonstrating dissemination in time in multiple sclerosis
    C Tur
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, Barcelona, Spain
    Mult Scler 14:631-5. 2008
    ....
  23. doi request reprint Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, MS Centre of Catalonia, Hospital Universitari Vall d Hebron, EUI 2a planta, Passeig de la Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol 257:742-6. 2010
    ..Results indicate that diplopia, facial sensory symptoms and gait disturbance occur in more than 30% of patients with CISB. Facial sensory symptoms are less associated with conversion to CDMS...
  24. doi request reprint A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat Edif EUI 2 feminine planta, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Brain 132:3353-65. 2009
    ....
  25. doi request reprint A functional magnetic resonance proof of concept pilot trial of cognitive rehabilitation in multiple sclerosis
    J Sastre-Garriga
    Hospital de Dia de Barcelona, Multiple Sclerosis Centre of Catalonia, Barcelona, Spain
    Mult Scler 17:457-67. 2011
    ..Cognitive rehabilitation is widely applied in neurorehabilitation settings. Functional magnetic resonance imaging (fMRI) may help in investigating changes in brain activity and provide a tool to assess the efficacy of rehabilitation...
  26. doi request reprint Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients
    J Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Barcelona, Spain
    Mult Scler 14:479-84. 2008
    ....
  27. ncbi request reprint Polyregional and hemispheric syndromes: a study of these uncommon first attacks in a CIS cohort
    R Pelayo
    Department of Neurology, Unit of Clinical Neuroinmunology, Hospital Universitari Vall d Hebron, Universitat Autonoma UAB, Barcelona, Spain
    Mult Scler 13:731-6. 2007
    ..There are differences between several studies in the definition, and, therefore, the prevalence of these so-called atypical CIS. Consensus on the denomination and definition of these syndromes must be reached...
  28. ncbi request reprint Long-term emotional state of multiple sclerosis patients treated with interferon beta
    J Porcel
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vail d Hebron, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Mult Scler 12:802-7. 2006
    ..To assess the long-term emotional state of multiple sclerosis (MS) patients treated with interferon beta (IFNbeta) for at least four years...
  29. ncbi request reprint Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?
    N Tellez
    Unitat de Neuroimmunologia Clinica, Edif EUI, Planta 2, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, 08035 Barcelona, Spain
    Mult Scler 11:198-202. 2005
    ..As a symptom of multiple sclerosis (MS), fatigue is difficult to manage because of its unknown etiology, the lack of efficacy of the drugs tested to date and the absence of consensus about which would be the ideal measure to assess fatigue...
  30. ncbi request reprint Fatigue in multiple sclerosis persists over time: a longitudinal study
    N Tellez
    2a planta EUI Unitat de Neuroimmunología, Clínica Hospital, Universitari Vall d Hebron Ps, Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 253:1466-70. 2006
    ..The aim of our study was to investigate changes in fatigue in a large cohort of MS patients and to determine the relationship between changes in disability and depression with changes in fatigue severity...
  31. doi request reprint Value of NMO-IgG determination at the time of presentation as CIS
    C Costa
    Unitat de Neuroimmunologia Clinica UNIC, Centre d Esclerosi Mu ltiple de Catalunya, Vall d Hebron Institut de Recerca, Barcelona, Spain
    Neurology 78:1608-11. 2012
    ..Despite the availability of diagnostic criteria, an overlap between neuromyelitis optica (NMO) and multiple sclerosis (MS) exists, particularly in the early stage of the disease...
  32. ncbi request reprint New diagnostic criteria for multiple sclerosis: application in first demyelinating episode
    M Tintore
    Clinical Neuroimmunology Unit, Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 60:27-30. 2003
    ....
  33. ncbi request reprint Decreased MMP-9 production in primary progressive multiple sclerosis patients
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Vail d Hebron, Barcelona, Espanya
    Mult Scler 10:376-80. 2004
    ..However, data regarding primary progressive (PP) MS is scarce...
  34. ncbi request reprint [Acute disseminated encephalomyelitis: study of factors involved in a possible development towards multiple sclerosis]
    C Tur
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona
    Neurologia 23:546-54. 2008
    ..Our work supports that also observed in recent publications: that both conversion to MS or presence of sequelae after an episode of ADEM are more frequent than traditionally considered...
  35. ncbi request reprint Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Escola d Infermeria, Barcelona, Espana
    Mult Scler 9:39-43. 2003
    ..The aim of this study was to investigate conversion to MS in patients with CISB...
  36. ncbi request reprint The basal ganglia: a substrate for fatigue in multiple sclerosis
    N Tellez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    Neuroradiology 50:17-23. 2008
    ..We aimed to study the relationship between fatigue in MS and the presence of focal dysfunction in the basal ganglia and frontal white matter...
  37. ncbi request reprint Expression of chemokine receptors in the different clinical forms of multiple sclerosis
    E M Martínez-Cáceres
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 8:390-5. 2002
    ..These results support that chemokines and their receptors are involved in the pathogenesis of MS However, a pattem of chemokine-chemokine receptor expression characteristic of each clinical form of the disease failed to be observed...
  38. doi request reprint Plasma levels of 15d-PGJ are not altered in multiple sclerosis
    M Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Eur J Neurol 16:1197-201. 2009
    ..The 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) is a peroxisome proliferator-activated receptor-gamma agonist with potent anti-inflammatory properties. It has been suggested that 15d-PGJ(2) may modulate multiple sclerosis (MS)...
  39. ncbi request reprint IFN-beta treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing-remitting multiple sclerosis
    C Espejo
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 10:630-5. 2004
    ..These data support that one of the immunomodulatory effects of IFN-beta treatment in MS may be a limitation of the autoimmune response modifying the CD80:CD28/CTLA-4 pathway...
  40. doi request reprint Antiviral immune response in patients with multiple sclerosis and healthy siblings
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 16:355-8. 2010
    ..We conclude that elevated IgG responses towards EBNA1 are associated with the development of multiple sclerosis...
  41. doi request reprint Plasma chitotriosidase activity in multiple sclerosis
    M Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 131:216-22. 2009
    ..Although these findings suggest a role of Chit in MS, our data do not support an association between plasma Chit activity and MS clinical course and clinical response to IFNbeta treatment...
  42. doi request reprint Brain volumetry counterparts of cognitive impairment in patients with multiple sclerosis
    J Sastre-Garriga
    Hospital de Dia de Barcelona, Multiple Sclerosis Centre of Catalonia CEM Cat, Fundació Esclerosi Múltiple, Barcelona, Spain
    J Neurol Sci 282:120-4. 2009
    ..Voxel-based morphometry (VBM) aims to identify regional differences in the local composition of brain tissue and makes possible to correlate these findings with cognitive impairment patterns...
  43. ncbi request reprint [Spanish multi-centre observational study of the first attacks suggestive of multiple sclerosis: the PREM cohort]
    Jaume Sastre-Garriga
    Unidad de Neuroinmunología Clínica, Centre d esclerosi multiple de Catalunya, Espana
    Rev Neurol 53:577-83. 2011
    ..Our aim is to determine whether the results from follow-ups in these studies are reproducible within a Spanish multi-centre context...
  44. ncbi request reprint Myelopathy in seronegative Sjögren syndrome and/or primary progressive multiple sclerosis
    I Pericot
    Unitat de Neuroimmunologia Clinica, Escola d enfermeria, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 9:256-9. 2003
    ..The relationship between multiple sclerosis (MS) and Sjögren syndrome (SS) is controversial. Nine patients, previously diagnosed with primary progressive MS (PPMS) and who fulfilled the diagnostic criteria for SS, are described...
  45. ncbi request reprint Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis
    I Duran
    Servei de Neurologia, Hospital Vall d Hebron, Barcelona, Spain
    Mult Scler 7:151-6. 2001
    ..We found a similar percentage of cytokines producing cells between healthy controls and the different clinical forms of multiple sclerosis patients...
  46. ncbi request reprint Neuromyelitis optica diagnosis in clinically isolated syndromes suggestive of multiple sclerosis
    M Rubiera
    Unitat de Neuroinmunologia Clínica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Neurology 66:1568-70. 2006
    ..2%) patients fulfilled NMO absolute criteria at some time and 1 (0.3%) also fulfilled one major supportive criterion. Therefore, even by systematically applying NMO criteria in patients with CIS, NMO diagnosis is reached infrequently...
  47. doi request reprint Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis
    E Canto
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mult Scler 18:983-90. 2012
    ..Chitinase 3-like 1 (CHI3L1) is upregulated in a wide variety of inflammatory conditions. Recent studies have pointed to a role of CHI3L1 in multiple sclerosis (MS) pathogenesis...
  48. ncbi request reprint [Diffuse astrocytoma presenting as an optic-spinal syndrome]
    I Parees
    Unidad de Neuroinmunología Clínica, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Rev Neurol 48:354-6. 2009
    ..Nevertheless, differentiation from inflammatory demyelinating diseases of the central nervous system can be challenging in some clinical situations. A patient with an optic-spinal syndrome due to a fibrillary astrocytoma is described...
  49. ncbi request reprint Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b
    C Borras
    Unit of Clinical Neuroimmunology, Hospital Vall d Hebron, Barcelona, Spain
    Neurology 52:1636-9. 1999
    ..Depression has been cited as a possible side effect of interferon beta-1b (IFNbeta-1b) therapy in patients with MS. This association remains unproven because of a lack of longitudinal studies...
  50. doi request reprint Roles of the ubiquitin peptidase USP18 in multiple sclerosis and the response to interferon-β treatment
    S Malhotra
    Servei de Neurologia Neuroimmunologia, Centre d esclerosi múltiple de Catalunya CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Eur J Neurol 20:1390-7. 2013
    ....
  51. pmc Cellular immune responses in multiple sclerosis patients treated with interferon-beta
    M F Bustamante
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Exp Immunol 171:243-6. 2013
    ..These findings do not support differential cellular immune responses in PBMC at baseline between IFN-β responders and non-responders...
  52. ncbi request reprint Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules
    I Duran
    Unitat de Neuroimmunologia Clinica, Servei de Neurologia, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Brain 122:2297-307. 1999
    ....
  53. ncbi request reprint The immune response against herpesvirus is more prominent in the early stages of MS
    P Villoslada
    Neuroimmunology Unit, Hospital Vall d Hebron, Barcelona, Spain
    Neurology 60:1944-8. 2003
    ..To assess antibody levels against human herpesvirus type 6 (HHV-6), Epstein-Barr virus (EBV), and Chlamydia pneumoniae (CP) in serum from individuals in the early and late phase of MS...
  54. doi request reprint Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis
    M Camina-Tato
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Pg Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 213:142-7. 2009
    ..We identified a risk haplotype associated with relapse-onset MS. These findings support the hypothesis that BTG1 polymorphisms may influence genetic predisposition for MS, especially in relapse-onset MS patients...
  55. doi request reprint TRPM4 mRNA expression levels in peripheral blood mononuclear cells from multiple sclerosis patients
    S Malhotra
    Department of Neurology Neuroimmunology, Centre d esclerosi multiple de Catalunya, Cemcat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 261:146-8. 2013
    ..These findings do not support a role of TRPM4 in the peripheral blood compartment of MS patients. ..
  56. doi request reprint SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis
    S Malhotra
    Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Spain
    Mult Scler 19:524-31. 2013
    ..Sialic acid binding immunoglobulin-like lectins (Siglecs) are cell surface receptors that recognize sialic acids and may attenuate immune responses and reduce inflammation...
  57. doi request reprint [Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis]
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Centre d esclerosi múltiple de Catalunya CEM Cat, Hospital Vall d Hebron, Barcelona, Espana
    Neurologia 26:556-62. 2011
    ..Along with these, we have also seen the appearance of a group of drugs which, instead of being defined by their route of administration, are considered together as a consequence of their similar design: the monoclonal antibodies...
  58. pmc Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats
    I Sáez-Torres
    Unitat de Neuroimmunologia Clinica, Department of Neurology, Hospital General Vall d Hebron, Universitat Autonoma de Barcelona, Universitat Politecnica de Catalunya, ETSEIB, Barcelona, Spain
    Clin Exp Immunol 121:151-6. 2000
    ..Lymph node cell proliferation and IL-4 and interferon-gamma production were also studied. We conclude that peptide T neither prevents nor ameliorates EAE in Lewis rats...
  59. ncbi request reprint Workshop on primary progressive multiple sclerosis: meeting summary
    X Montalban
    Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Barcelona, Spain
    Mult Scler 8:177-8. 2002
  60. ncbi request reprint Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice
    C Espejo
    , Hospital Vall d'Hebron, Barcelona, 08035, Spain
    Exp Neurol 172:460-8. 2001
    ..These results suggest a putative alternative mechanism of action of this cytokine that works independent of its receptor...
  61. ncbi request reprint Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial
    J Rio
    Centres H Vall d Hebron, Barcelona, Spain
    Neurology 63:525-8. 2004
    ..To compare the efficacy of acetaminophen, ibuprofen, and prednisone in the treatment of interferon beta-1a (IFNbeta-1a) flu-like syndrome (FLS)...
  62. ncbi request reprint [Spanish adaptation of the disease-specific questionnaire MSQOL-54 in multiple sclerosis patients]
    M Aymerich
    Agència d Avaluació de Tecnologia i Recerca Mèdiques, Hospital Universitari Vall d Hebron, Barcelona
    Neurologia 21:181-7. 2006
    ..The objective of this study was to develop the Spanish version of the MSQOL-54 and to obtain a conceptually equivalent version to the original one for its use in patients with MS in the first phase of the project...
  63. ncbi request reprint Time-course expression of CNS inflammatory, neurodegenerative tissue repair markers and metallothioneins during experimental autoimmune encephalomyelitis
    C Espejo
    Unitat de Neuroimmunologia Clinica, Hospital Universitari, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    Neuroscience 132:1135-49. 2005
    ....
  64. doi request reprint Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis
    J E Martinez-Rodriguez
    Neurology Service, Parc de Salut Mar, IMIM Hospital del Mar Research Institute, Barcelona, Spain
    Clin Immunol 141:348-56. 2011
    ..Our results reveal that IFNβ may promote in responders changes in the NK cell immunophenotype, corresponding to the profile found at early maturation stages of this lymphocyte lineage...
  65. ncbi request reprint [Clinical spectrum associated with aquaporin-4 antibodies (NMO-IgG)]
    Y Blanco
    Servei de Neurologia, Hospital Clinic, Universitat de Barcelona e Institut d Investigació August Pi i Sunyer IDIBAPS, Barcelona, Espana
    Neurologia 25:5-12. 2010
    ....
  66. ncbi request reprint [Calcified cerebral metastases. Study of two cases and review of literature]
    J Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital General de la vall d Hebron, Barcelona
    Neurologia 15:136-9. 2000
    ..So, facing calcified intracranial lesions, metastatic origin should be considered in the differential diagnosis, pulmonary tumours being the first to be ruled out...
  67. ncbi request reprint Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis
    J Sastre-Garriga
    , H. Universitari Vall d'Hebron, Barcelona, Spain
    Ann Neurol 49:408-11. 2001
    ..ACA tests should be performed only when a suspicion of PAPS is raised and atypical clinical presentation for MS is found...
  68. doi request reprint IL28B polymorphisms are not associated with the response to interferon-β in multiple sclerosis
    S Malhotra
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Passeig Vall d Hebron 119 129, Barcelona, Spain
    J Neuroimmunol 239:101-4. 2011
    ..These findings do not support a role of IL28B polymorphisms in the response to IFNβ in MS patients...
  69. ncbi request reprint [Listeria rhombencephalitis. Neuroradiological findings]
    I Pericot
    Servei de Neurologia, Unitat de Neuroimmunologia Clinica, Barcelonal, Espana
    Neurologia 18:34-7. 2003
    ..Both patients had a favorable outcome with full clinical recovery. We conclude that MRI aids in the early detection of parenchymal infections, therefore, MRI is crucial for early diagnosis and is very useful for follow-up examinations...
  70. ncbi request reprint [Modafinil and fatigue in multiple sclerosis]
    N Tellez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona
    Neurologia 19:434-7. 2004
    ..Although few studies exist on modafinil in MS patients with fatigue, the results suggest this drug as a promising treatment, because of its efficacy and safety, and should encourage us to continue working in this area...
  71. ncbi request reprint Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
    ....
  72. ncbi request reprint [Natalizumab in multiple sclerosis]
    J Río-Izquierdo
    Centre d esclerosi multiple de Catalunya, Hospital Universitari Vall d Hebron, Barcelona, Espana
    Rev Neurol 49:265-9. 2009
    ..Natalizumab is well tolerated, although severe side effects have been reported that have conditioned its use as a second-line drug for the treatment of multiple sclerosis in patients who do not respond to conventional immunomodulators...
  73. ncbi request reprint APS and the brain
    J Sastre-Garriga
    Unitat de Neuroimmunology Clínica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Lupus 12:877-82. 2003
    ....
  74. doi request reprint Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis
    Robert Goertsches
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, 08035 Barcelona, Spain
    Mult Scler 14:412-4. 2008
    ..Transcript expression in brain lesions from MS patients was increased. These findings suggest C10orf27 as a candidate gene for MS susceptibility and pathogenesis...
  75. ncbi request reprint Altered maturation of circulating dendritic cells in primary progressive MS patients
    Cristina Lopez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, HUVH, Barcelona, Spain
    J Neuroimmunol 175:183-91. 2006
    ..These results suggest an impaired maturation state of DC in PPMS patients, and a beneficial effect of IFN-beta favouring the survival of PDC and promoting a Th2 environment...
  76. ncbi request reprint Interferon-beta 1b in the treatment of multiple sclerosis
    Jordi Rio
    Clinical Neuroimmunology Unit, Vall d Hebron University Hospital, 08035 Barcelona, Spain
    Expert Opin Pharmacother 6:2877-86. 2005
    ..In the face of a proportion of RRMS patients experiencing a poor response to the drug, other therapeutic approaches need to be considered...
  77. ncbi request reprint Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients
    Jordi Rio
    2TM planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 59:344-52. 2006
    ..Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response...
  78. ncbi request reprint Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis
    Carlos Nos
    Unitat de Neuroimmunologia Clinica, Hospital Vall d Hebron, Barcelona, Spain
    Mult Scler 10:413-6. 2004
    ....
  79. ncbi request reprint Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone
    Nieves Téllez
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, 08035 Barcelona, Spain
    Mult Scler 12:487-94. 2006
    ..Fatigue is one of the most limiting symptoms in multiple sclerosis (MS) and the mechanisms underlying its origin are poorly understood. Our aim was to test whether fatigue in MS is associated with endocrine markers...
  80. ncbi request reprint TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Escuela de Enfermeria 2a planta, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neurol 253:701-6. 2006
    ..These findings point to different regulatory mechanisms of the TACE-TNF-alpha pathway in the clinical MS subtypes and expand the role of TACE in MS pathogenesis...
  81. doi request reprint A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis
    Alex Rovira
    Magnetic Resonance Unit, Department of Radiology, Hospital Vall d Hebron, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 66:587-92. 2009
    ....
  82. doi request reprint Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Edifici Escola d Infermeria 2 feminine planta, Passeig Vall d Hebron 119 129, 08035 Barcelona, Spain
    Arch Neurol 66:972-8. 2009
    ..However, not all patients respond to interferon beta therapy, and to date there is a lack of surrogate markers that reliably correlate with responsiveness to interferon beta therapy in MS...
  83. doi request reprint Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS
    Eva Julià
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH Universitat Autònoma de Barcelona, Barcelona, Spain
    Clin Immunol 133:364-74. 2009
    ....
  84. ncbi request reprint Plasma osteopontin levels in multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Escola d Infermeria 2a planta, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neuroimmunol 158:231-9. 2005
    ....
  85. doi request reprint Predicting responders to therapies for multiple sclerosis
    Jordi Rio
    Multiple Sclerosis Centre of Catalonia, Vall d Hebron University Hospital, Passeig Vall d Hebron 119 120, Barcelona, Spain
    Nat Rev Neurol 5:553-60. 2009
    ..We evaluate the roles of clinical measures, MRI and pharmacogenomics in these processes...
  86. ncbi request reprint Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035, Barcelona, Spain
    J Neurol 252:795-800. 2005
    ..We present the data of our cohort of relapsing-remitting multiple sclerosis (RRMS) patients treated with interferon beta (IFNbeta)...
  87. doi request reprint Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona 08035, Spain
    Brain 133:1082-93. 2010
    ....
  88. ncbi request reprint Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients
    Manuel Comabella
    Department of Neurology, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 10:618-20. 2004
    ..We found no evidence of association between SLC11A1 polymorphisms and MS susceptibility in the Spanish population...
  89. doi request reprint Fingolimod for relapsing multiple sclerosis: an update
    Alejandro Horga
    Multiple Sclerosis Centre of Catalonia CEM Cat, Vall d Hebron University Hospital, Passeig Vall d Hebron, 119 129, 08035 Barcelona, Spain
    Expert Opin Pharmacother 11:1183-96. 2010
    ..Fingolimod is an oral sphingosine-1-phosphase (S1P) receptor modulator under clinical investigation for the treatment of relapsing-remitting and primary progressive MS...
  90. ncbi request reprint The pros and cons of early treatment of relapsing forms of multiple sclerosis
    Xavier Montalban
    Unit of Clinical Neuroimmunology, Hospitals Vall d Hebron EUI 2a PI, Psg Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol 251:IV30-4. 2004
    ....
  91. ncbi request reprint Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis
    Xavier Montalban
    University Hospital Vall d Hebron, Unitat de Neuroimmunologia Clinica, Pg Val d Hebron 119 129 EUI 2a P E 08035, Barcelona, Spain
    Mult Scler 10:S62; discussion 62-4. 2004
    ..Significant differences favouring interferon beta-1b in the MSFC score, T2 lesion volume and TI lesion volume at 24 months were observed. Further study of interferon beta-Ib therapy in PPMS patients in warranted...
  92. ncbi request reprint Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 52:400-6. 2002
    ....
  93. ncbi request reprint The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta
    Pablo Villoslada
    Neuroimmunology Unit, Hospital Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 130:194-201. 2002
    ..Similarly, no difference in the distribution of responders and nonresponders to interferon-beta (IFNB) therapy, as defined by primary and secondary end points, was observed when individuals were stratified according to HLA-DR2 status...
  94. doi request reprint Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, CEM Cat, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    Clin Immunol 130:145-50. 2009
    ..The early and sustained increase in TIMP-1 levels could be a marker of the response to IFN-b during the first 2 years of treatment...
  95. doi request reprint FTY720 (fingolimod) for relapsing multiple sclerosis
    Alejandro Horga
    Clinical Neuroinmunology Unit, Multiple Sclerosis Center of Catalonia CEM Cat, Vall d Hebron University Hospital, Barcelona, Spain
    Expert Rev Neurother 8:699-714. 2008
    ..These results are awaiting confirmation in the three ongoing Phase III clinical trials evaluating FTY720 for relapsing-remitting multiple sclerosis...
  96. doi request reprint B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS
    Manuel Comabella
    Centre d esclerosi multiple de Catalunya, CEM Cat, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Barcelona, Spain
    J Neuroimmunol 223:135-7. 2010
    ....
  97. ncbi request reprint Interferon beta in secondary progressive multiple sclerosis : daily clinical practice
    Jordi Rio
    2a planta EUI, Unitat de Neuroimmunología Clínica Hospital Universitario Vall d Hebron, Psg Vall d Hebron 119 120, 08035 Barcelona, Spain
    J Neurol 254:849-53. 2007
    ..We present the data from a cohort of secondary progressive multiple sclerosis (SPMS) patients treated with interferon beta (IFNbeta-1b) at our MS clinic...
  98. pmc Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects
    E M Martínez-Cáceres
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Clin Exp Immunol 127:165-71. 2002
    ..However, no conclusion can be drawn as to a possible long-term or even intermediate influence of ivMP treatment on the course of the disease...
  99. ncbi request reprint Anticholinesterasics in the treatment of cognitive impairment in multiple sclerosis
    J Porcel
    2a planta EUI, Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Ps Vall d Hebron 119 129, 08035, Barcelona, Spain
    J Neurol Sci 245:177-81. 2006
    ..Finally, we discuss future issues to take into consideration for AChEI treatments in the context of MS...
  100. ncbi request reprint Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G-->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family
    M Comabella
    Department of Neurology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Ann Neurol 50:108-12. 2001
    ..This case indicates that adult metachromatic leukodystrophy should be considered in adult patients with demyelinating peripheral neuropathy of unknown etiology...
  101. ncbi request reprint Unconventional therapy in multiple sclerosis
    Jaume Sastre-Garriga
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 9:320-2. 2003
    ..The use of unconventional therapies is growing in western countries. Few studies on their frequency and rationale among multiple sclerosis (MS) patients have been carried out in Europe...